United Kingdom (UK)
Recombinant monoclonal antibody to CD20. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma VET308 (CD20-5).
UniProt Accession Number of Target Protein: Q3C2E2
Alternative Name(s) of Target: MS4A1; B-lymphocyte antigen CD20; Membrane-spanning 4-domains subfamily A member 1
Immunogen: The original antibody was generated by immunizing mice with CHO-DG44 cells expressing canine CD20.
Specificity: This antibody binds canine (dog) CD20 and cross reacts with feline (cat) CD20. This protein plays an important role in the regulation of cellular calcium influx necessary for development, differentiation, and activation of B-lymphocytes.
Application Notes: The binding reactivity of this antibody to recombinant dog and cat CD20 expressed on the surface of CHO cells was determined using flow cytometry. This antibody binds recombinant dog CD20 with a binding affinity of Kd= 1.2 nM. This antibody exhibited a strong staining of B cells in a immunohistochemical staining of lymph node tissues collected from dogs with B-cell lymphoma. The ability of this antibody to alter the proliferation of lymphoma cells was checked using cell assays. This antibody was reported to cause a 60% reduction in proliferation of lymphoma cells (US9616120).
Antibody first published in: PMID: